首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1681246篇
  免费   124401篇
  国内免费   3676篇
耳鼻咽喉   21703篇
儿科学   55443篇
妇产科学   46037篇
基础医学   239366篇
口腔科学   48645篇
临床医学   149296篇
内科学   329633篇
皮肤病学   38637篇
神经病学   130156篇
特种医学   63731篇
外国民族医学   242篇
外科学   256310篇
综合类   38791篇
一般理论   531篇
预防医学   122975篇
眼科学   39947篇
药学   122993篇
  7篇
中国医学   4344篇
肿瘤学   100536篇
  2019年   13263篇
  2018年   19612篇
  2017年   15034篇
  2016年   16416篇
  2015年   18745篇
  2014年   26123篇
  2013年   37871篇
  2012年   52691篇
  2011年   55375篇
  2010年   32705篇
  2009年   30638篇
  2008年   51476篇
  2007年   54745篇
  2006年   55190篇
  2005年   52487篇
  2004年   50684篇
  2003年   48059篇
  2002年   46266篇
  2001年   91694篇
  2000年   93455篇
  1999年   76614篇
  1998年   18780篇
  1997年   16270篇
  1996年   16421篇
  1995年   16637篇
  1994年   15234篇
  1993年   14002篇
  1992年   57316篇
  1991年   55265篇
  1990年   52940篇
  1989年   50725篇
  1988年   46115篇
  1987年   44926篇
  1986年   42204篇
  1985年   39986篇
  1984年   29318篇
  1983年   24852篇
  1982年   13847篇
  1981年   12328篇
  1979年   25475篇
  1978年   17526篇
  1977年   14844篇
  1976年   13802篇
  1975年   14490篇
  1974年   17580篇
  1973年   16889篇
  1972年   15645篇
  1971年   14425篇
  1970年   13408篇
  1969年   12490篇
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
3.
Modified-release opioids are often prescribed for the management of moderate to severe acute pain following total hip and knee arthroplasty, despite recommendations against their use due to increasing concerns regarding harm. The primary objective of this multicentre study was to examine the impact of modified-release opioid use on the incidence of opioid-related adverse events compared with immediate-release opioid use, among adult inpatients following total hip or knee arthroplasty. Data for total hip and knee arthroplasty inpatients receiving an opioid analgesic for postoperative analgesia during hospitalisation were collected from electronic medical records of three tertiary metropolitan hospitals in Australia. The primary outcome was the incidence of opioid-related adverse events during hospital admission. Patients who received modified with or without immediate-release opioids were matched to those receiving immediate-release opioids only (1:1) using nearest neighbour propensity score matching with patient and clinical characteristics as covariates. This included total opioid dose received. In the matched cohorts, patients given modified-release opioids (n = 347) experienced a higher incidence of opioid-related adverse events overall, compared with those given immediate-release opioids only (20.5%, 71/347 vs. 12.7%, 44/347; difference in proportions 7.8% [95%CI 2.3–13.3%]). Modified-release opioid use was associated with an increased risk of harm when used for acute pain during hospitalisation after total hip or knee arthroplasty.  相似文献   
4.
5.
Pharmaceutical Research - The quality testing and approval procedure for most pharmaceutical products is a streamlined process with standardized procedures for the determination of critical quality...  相似文献   
6.
Renal cell cancer (RCC) represents 2%-3% of all adulthood cancers and is the most common malignant neoplasm of the kidney (90%). In the mid-nineties of the last century, the standard of treatment for patients with metastatic RCC was cytokines. Sunititib and pazopanib were registered in 2007 and 2009, respectively, and have since been the standard first-line treatment for metastatic clear cell RCC (mccRCC). Renal cell cancer is a highly immunogenic tumor with tumor infiltrating cells, including CD8+ T lymphocytes, dendritic cells, natural killer cells (NK) and macrophages. This observation led to the design of new clinical trials in which patients were treated with immunotherapy. With the growing evidence that proangiogenic factors can have immunomodulatory effects on the host’s immune system, the idea of combining angiogenic drugs with immunotherapy has emerged, and new clinical trials have been designed. In the last few years, several therapeutic options have been approved [immunotherapy and immunotherapy/tyrosine kinase inhibitors (TKI)] for the first-line treatment of mccRCC. Nivolumab/ipilimumab is approved for the treatment of patients with intermediate and poor prognoses. Several checkpoint inhibitors (pembrolizumab, nivolumab, avelumab) in combination with TKI (axitinib, lenvatinib, cabozantinib) are approved for the treatment of patients regardless of their International mRCC Database Consortium prognostic group and PD-L1 expression. There is no specific and ideal biomarker that could help in selecting the ideal patient for the appropriate first-line treatment.  相似文献   
7.
Neuroscience and Behavioral Physiology - We present here results from analysis of the formation of brain bioelectrical activity in children and adolescents living in the northern region of Russia...  相似文献   
8.
9.
10.
Journal of Pharmacokinetics and Pharmacodynamics - The integration between physiologically-based pharmacokinetics (PBPK) models and pharmacodynamics (PD) models makes it possible to describe the...  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号